Introduction.
Dactinomycin is a potent antitumor antibiotic whose clinical use is limited by severe systemic toxicity. Nanoparticle carriers can protect drug cargo, modulate release, improve pharmacokinetics, and potentially promote passive tumor accumulation through the enhanced permeability and retention (EPR) effect. Poly(lactic-co-glycolic acid) (PLGA) is a biodegradable and biocompatible polymer with an established regulatory history and use in FDA-approved drug products. Furthermore, cancer-cell-membrane coatings may retain membrane-associated adhesion proteins and promote homotypic recognition of tumor cells originating from the same cancer type. This study aimed to develop dactinomycin-loaded PLGA nanoparticles functionalized with B16 murine melanoma cell membranes.
Methods.
Dactinomycin-loaded PLGA nanoparticles were prepared by single-emulsion solvent evaporation and optimized using a Box–Behnken design. Particle size, polydispersity index, and zeta potential were determined by dynamic and electrophoretic light scattering; drug content was measured spectrophotometrically, and morphology was evaluated by transmission electron microscopy. B16 membrane material was obtained by hypotonic lysis combined with ultrasonication, centrifugation, and size-exclusion chromatography. Nanoparticles and membrane protein were mixed at a 1:1 mass ratio and processed by probe sonication for 3 min at 45% amplitude and 70 W in an ice bath, followed by centrifugation. Membrane association was evaluated by bicinchoninic acid assay, SDS–PAGE, densitometry, and changes in physicochemical parameters. Drug release was studied in phosphate-buffered saline at +37°C. Cytotoxicity and cellular uptake in B16 cells were assessed by MTT assay and flow cytometry, respectively.
Results.
Optimized uncoated nanoparticles had a mean diameter of 243 nm, a polydispersity index of 0.129, a zeta potential of -22.1 mV, a drug content of 2.06 wt.%, and an encapsulation efficiency of 63.39%. Transmission electron microscopy confirmed a spherical morphology. Approximately 77% of dactinomycin was released within 24 h, and the Weibull model best described the biphasic release profile. Following membrane functionalization, particle diameter increased to 256 nm, the polydispersity index to 0.220, and the zeta potential shifted to -20.8 mV. The biomimetic nanoparticle pellet contained 0.125 mg protein, while SDS–PAGE and densitometry demonstrated membrane-derived protein fractions. Membrane-functionalized nanoparticles showed significantly greater cellular uptake after 4 and 24 h and more than twofold higher cytotoxic activity than uncoated dactinomycin-loaded nanoparticles.
Conclusions.
A biomimetic PLGA-based dactinomycin delivery system coated with B16 melanoma cell membranes was successfully developed and characterized. Membrane functionalization improved nanoparticle interaction with melanoma cells, resulting in enhanced uptake and increased cytotoxicity in vitro. These findings support the potential of this biomimetic platform for targeted melanoma therapy and justify further in vivo investigation.